Prudential PLC Sells 88,665 Shares of Pfizer Inc. $PFE

Prudential PLC lessened its stake in Pfizer Inc. (NYSE:PFE) by 11.2% in the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 704,862 shares of the biopharmaceutical company’s stock after selling 88,665 shares during the period. Prudential PLC’s holdings in Pfizer were worth $17,551,000 at the end of the most recent reporting period.

Other hedge funds have also made changes to their positions in the company. Horizon Financial Services LLC lifted its stake in Pfizer by 174.8% during the fourth quarter. Horizon Financial Services LLC now owns 1,014 shares of the biopharmaceutical company’s stock worth $25,000 after purchasing an additional 645 shares during the period. Godfrey Financial Associates Inc. bought a new position in Pfizer during the fourth quarter worth about $26,000. YANKCOM Partnership bought a new position in Pfizer during the fourth quarter worth about $28,000. HFM Investment Advisors LLC lifted its stake in Pfizer by 61.0% during the fourth quarter. HFM Investment Advisors LLC now owns 1,127 shares of the biopharmaceutical company’s stock worth $28,000 after purchasing an additional 427 shares during the period. Finally, Darwin Wealth Management LLC bought a new position in Pfizer during the second quarter worth about $32,000. Institutional investors own 68.36% of the company’s stock.

Wall Street Analyst Weigh In

A number of research analysts have commented on the stock. CICC Research assumed coverage on shares of Pfizer in a research note on Thursday, April 16th. They set an “outperform” rating and a $33.00 price target for the company. Zacks Research upgraded shares of Pfizer from a “strong sell” rating to a “hold” rating in a research note on Tuesday, February 24th. BMO Capital Markets restated an “outperform” rating and set a $30.00 price target on shares of Pfizer in a research note on Monday, March 9th. Royal Bank Of Canada restated an “underperform” rating and set a $25.00 price target on shares of Pfizer in a research note on Monday, April 20th. Finally, Bank of America cut their price target on shares of Pfizer from $27.00 to $26.00 and set a “neutral” rating for the company in a research note on Thursday, April 9th. One research analyst has rated the stock with a Strong Buy rating, five have given a Buy rating, eleven have assigned a Hold rating and three have assigned a Sell rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Hold” and an average target price of $28.82.

Pfizer News Roundup

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Pfizer highlighted fresh oncology progress, including new and advancing clinical studies in lung cancer and bladder cancer, which could strengthen its long-term cancer pipeline if the early data continue to trend well. Pfizer’s New Lung Cancer Study Signals Fresh Oncology Upside for PFE Investors
• Positive Sentiment: The company also expanded its oncology pipeline with a new combination trial in advanced lung cancer, reinforcing the market’s view that cancer treatments remain a key growth area for Pfizer. Pfizer Expands Oncology Pipeline With New PF-08634404 Combo Trial in Advanced Lung Cancer
• Positive Sentiment: Pfizer signed a license agreement with Chai Discovery to use AI for drug discovery, signaling a push to speed up research and improve pipeline productivity over time. Chai Discovery Announces License Agreement with Pfizer to Accelerate Drug Discovery with AI
• Neutral Sentiment: Pfizer and Astellas advanced an early bladder cancer combination trial, which is encouraging scientifically but still too early to materially change near-term financial expectations. Pfizer and Astellas Advance New Bladder Cancer Combo in Early Clinical Trial
• Neutral Sentiment: Pfizer’s conference presentation and several study updates on tofacitinib and bevacizumab biosimilars are incremental developments, but they are unlikely to move the stock on their own. Pfizer Inc. (PFE) Presents at Jefferies Global Healthcare Conference 2026 Transcript
• Negative Sentiment: Investor sentiment is still being weighed down by concerns that Pfizer is down about 4.5% since its last earnings report, suggesting the market remains focused on slower post-earnings momentum and earnings estimate pressure. Why Is Pfizer (PFE) Down 4.5% Since Last Earnings Report?

Pfizer Stock Performance

NYSE PFE opened at $25.70 on Friday. The firm has a market cap of $146.46 billion, a price-to-earnings ratio of 19.62 and a beta of 0.34. The company has a 50 day moving average of $26.65 and a 200-day moving average of $26.29. The company has a current ratio of 1.25, a quick ratio of 0.94 and a debt-to-equity ratio of 0.67. Pfizer Inc. has a 1-year low of $23.08 and a 1-year high of $28.75.

Pfizer (NYSE:PFE) last posted its quarterly earnings data on Tuesday, May 5th. The biopharmaceutical company reported $0.75 earnings per share for the quarter, topping the consensus estimate of $0.72 by $0.03. The company had revenue of $14.45 billion during the quarter, compared to analyst estimates of $13.84 billion. Pfizer had a net margin of 11.83% and a return on equity of 19.44%. The company’s revenue was up 5.4% on a year-over-year basis. During the same quarter last year, the business posted $0.92 earnings per share. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. On average, equities analysts forecast that Pfizer Inc. will post 2.99 earnings per share for the current fiscal year.

Pfizer Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Friday, June 12th. Stockholders of record on Friday, May 8th will be issued a dividend of $0.43 per share. The ex-dividend date of this dividend is Friday, May 8th. This represents a $1.72 annualized dividend and a dividend yield of 6.7%. Pfizer’s dividend payout ratio (DPR) is presently 131.30%.

Pfizer Company Profile

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.